학술논문

19p13.1 is a triple negative-specific breast cancer susceptibility locus
Document Type
Author
Stevens, Kristen NFredericksen, ZacharyVachon, Celine MWang, XianshuMargolin, SaraLindblom, AnnikaNevanlinna, HeliGreco, DarioAittomäki, KristiinaBlomqvist, CarlChang-Claude, JennyVrieling, AlinaFlesch-Janys, DieterSinn, Hans-PeterWang-Gohrke, ShanNickels, StefanBrauch, HiltrudKo, Yon-DschunFischer, Hans-PeterNetwork, The GenicaSchmutzler, Rita KMeindl, AlfonsBartram, Claus RSchott, SarahEngel, ChristophGodwin, Andrew KWeaver, JoellenPathak, Harsh BSharma, PriyankaBrenner, HermannMuller, HeikoArndt, VolkerStegmaier, ChristaMiron, PenelopeYannoukakos, DrakoulisStavropoulou, AlexandraFountzilas, GeorgeGogas, Helen JSwann, RuthDwek, MiriamPerkins, Katherine AnneMilne, Roger LBenítez, JavierZamora, M PilarIgnacio Arias Pérez, JoséBojesen, Stig ENielsen, Sune FNordestgaard, Borge GFlyger, HenrikGuénel, PascalTruong, ThérèseMenegaux, FlorenceCordina-Duverger, EmilieBurwinkel, BarbaraMarmé, FrederickSchneeweiss, AndreasSohn, ChristofSawyer, ElinorTomlinson, IanKerin, Michael JPeto, JulianJohnson, NicholaFletcher, OliviaDos Santos Silva, IsabelFasching, Peter ABeckmann, Matthias WHartmann, ArndtEkici, Arif BLophatananon, ArtitayaMuir, KennethPuttawibul, PuttisakWiangnon, SuraponSchmidt, Marjanka KBroeks, AnnegienBraaf, Linde MRosenberg, Efraim HHopper, John LApicella, CarmelPark, Daniel JSouthey, Melissa CSwerdlow, Anthony JAshworth, AlanOrr, NickSchoemaker, Minouk JAnton-Culver, HodaZiogas, ArgyriosBernstein, LeslieClarke Dur, ChristinaShen, Chen-YangYu, Jyh-CherngHsu, Huan-MingHsiung, Chia-NiHamann, UteDünnebier, ThomasRüdiger, ThomasUlrich Ulmer, HansPharoah, Paul D PDunning, Alison MHumphreys, Manjeet KWang, QinCox, AngelaCross, Simon SReed, Malcolm W RHall, PerCzene, KamilaAmbrosone, Christine BAdemuyiwa, FolusoHwang, HelenaEccles, Diana MGarcia-Closas, MontserratFigueroa, Jonine DSherman, Mark ELissowska, JolantaDevilee, PeterSeynaeve, CarolineTollenaar, R A E MHooning, Maartje JAndrulis, Irene LKnight, Julia AGlendon, GordMulligan, Anna MarieWinqvist, RobertPylkäs, KatriJukkola-Vuorinen, ArjaGrip, MerviJohn, Esther MMiron, AlexanderGrenaker Alnaes, GretheKristensen, VesselaBorresen-Dale, Anne-LiseGiles, Graham GBaglietto, LauraMcLean, Catriona ASeveri, GianlucaKosel, Matthew LPankratz, V ShaneSlager, SusanOlson, Janet ERadice, PaoloPeterlongo, PaoloManoukian, SiranoushBarile, MonicaLambrechts, DietherHatse, SigridDieudonne, Anne-SophieChristiaens, Marie-RoseChenevix-Trench, GeorgiaInvestigators, KconfabGroup, AocsBeesley, JonathanChen, XiaoqingMannermaa, ArtoKosma, Veli-MattiHartikainen, Jaana MSoini, YlermiEaston, Douglas FCouch, Fergus J
Source
Cancer Research. 72:1795
Subject
Language
English
ISSN
0008-5472
1538-7445
Abstract
The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with risk of ovarian cancer. Here we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 Odds Ratio (OR)=1.10, 95% Confidence Interval (CI) 1.05 - 1.15, p=3.49 x 10-5] and triple negative (TN) (ER, PR and HER2 negative) breast cancer [rs8170 OR=1.22, 95% CI 1.13 - 1.31, p=2.22 x 10-7]. However, rs8170 was no longer associated with ER-negative breast cancer risk when TN cases were excluded [OR=0.98, 95% CI 0.89 - 1.07, p=0.62]. In addition, a combined analysis of TN cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC) (n=3,566) identified a genome-wide significant association between rs8170 and TN breast cancer risk [OR=1.25, 95% CI 1.18 - 1.33, p=3.31 x 10-13]. Thus, 19p13.1 is the first triple negative-specific breast cancer risk locus and the first locus specific to a histological subtype defined by ER, PR, and HER2 to be identified. These findings provide convincing evidence that genetic susceptibility to breast cancer varies by tumor subtype and that triple negative tumors and other subtypes likely arise through distinct etiologic pathways.